Teclistamab is a bispecific antibody approved by the FDA in October 2022 that targets the B-cell maturation antigen (BCMA) found on the surface of myeloma cells. It essentially recruits the body's immune system to attack and destroy these cancer cells.

Teclistamab is intended for patients with multiple myeloma that has progressed (relapsed) after receiving at least four prior lines of therapy, including an immunomodulatory agent (like lenalidomide or pomalidomide) and a proteasome inhibitor (like bortezomib or carfilzomib). It can also be used for patients whose myeloma did not respond well to initial treatment (refractory).

Teclistamab is given subcutaneously (via injection), once weekly. This is currently the only bispecific antibody whose dosing is based off of your body weight.

Patients who have maintained a complete response on teclistimab for at least six months may be eligible for a reduced dosage administered every other week.

As reported in teclistamab’s clinical trials, 72% of patients experienced some grade of CRS and 57% some grade of neurologic toxicities, including ICANS. Additionally, 84% of patients receiving teclistamab experienced low white blood cell counts (neutropenia), which significantly increases the risk of infections. Read more about teclistamab's safety profile. 

62% of patients treated with teclistamab responded to this therapy within the first 5 months of treatment, and 28% of patients achieved a complete response. 

For more information on teclistamab, visit tecvayli.com